What Happens to a Biotech's Share Price After Its First FDA Approval? Mesoblast and Clarity Pharmaceuticals on the ASX
Written by Christopher Hall, AdvDipFP | Authorised Representative, AFSL 526688 | Updated October 2026
Analysis sourced from Gary Glover (AR 259215), Authorised Representative, Novus Capital Limited (AFSL 238 168)
ASX biotech FDA approval stocks share one defining moment: the point a company's first product is cleared to sell commercially, when years of raising capital from the market can start turning into revenue earned from the product itself. Gary Glover, who reviews ASX momentum stocks in a recorded weekly session with Finer Market Points, is watching two ASX-listed biotechs through that exact lens right now — Mesoblast (ASX: MSB), which has already crossed that line, and Clarity Pharmaceuticals (ASX: CU6), which has not. With the ASX down roughly 8% from its recent highs as at this session, this article explains what FDA approval actually changes for a biotech's economics, how Gary is reading each stock's chart against that backdrop, and the two checks — fundamental and technical — he applies before sizing a position in either one.
Gary Glover reads Mesoblast's and Clarity Pharmaceuticals' charts against the ASX biotech FDA approval inflection — the point a company's first approved product can turn years of capital raising into revenue. This article explains the fundamental and technical checks behind both setups.
What Does FDA Approval Actually Change for an ASX Biotech Stock?
FDA approval is the point at which a biotech is legally permitted to sell its product commercially — converting what was a pipeline asset into a revenue line. Formally, this clearance — granted through a Biologics License Application or a New Drug Application — is what permits a company to market and sell a product in the United States. Before it, a biotech's only route to funding is the market itself: issuing new shares to cover the cost of clinical trials and regulatory work, which dilutes existing holders and is the default state for almost every pre-commercial biotech. After it, margins can start flowing directly from sales of the approved product — and if the company holds other candidates in late-stage development within the same therapeutic area, a first approval can make the next one more likely without a further return to the market for funding.
Gary Glover's anecdotal observation, developed across his trading career, is that Mesoblast illustrates this shift directly: after years of "tapping the market for funds," the company's first approved product has moved it toward "really starting to make some money." This is a practitioner observation, not a formal study — it describes how Gary reads the mechanism, not a documented research finding.
How Is Gary Glover Reading Mesoblast's Chart Right Now?
Mesoblast's price action has been tightening into the same level after months of wide swings — the technical half of the setup, alongside the fundamental shift described above. As read in Gary Glover's 06 October 2026 session, Mesoblast ran from around $2.00 to $2.80 in July 2026, twice retraced back toward $2.00, and its most recent bounces off that level have gotten progressively smaller.
Move | Approximate price |
July 2026 high | $2.80 |
First retracement | $2.00 |
Secondary high | $2.60 |
Most recent low | ~$2.00 (smaller bounce) |
Gary Glover's anecdotal observation, developed across his trading career, is that the fundamental shift above is exactly why the wide swings are worth waiting out:
"It doesn't potentially have to go to the market and tap the market for any funds here."
In Gary's framing, a stock no longer dependent on dilutive capital raises changes the risk profile of holding through a volatile chart — the business risk recedes even while the share-price risk remains. He has been watching Mesoblast for months specifically waiting for that volatility to narrow before considering a position, rather than buying into the wide swings directly.
This kind of narrowing range — a volatility contraction pattern tightening into a base — is the technical structure Gary looks for before sizing an entry, regardless of the underlying company's industry.
The FMP Momentum Profile — published daily and accessible to FMP YouTube Momentum Profile members — covers the broader ASX momentum universe Gary Glover reviews each week, giving members early access to the educational data discussed in sessions like this one.
Why Is Clarity Pharmaceuticals Still Waiting for a Catalyst?
Clarity Pharmaceuticals (ASX: CU6) shows a similar kind of tightening price action to Mesoblast's, but Gary Glover is explicit that this one still needs a catalyst before the technical setup means anything on its own. A tightening chart is necessary but not sufficient — Gary's anecdotal observation, developed across his trading career, is that Clarity Pharmaceuticals is "neglected" and under-covered at the moment, and a narrowing-range pattern without a near-term approval or clinical-data catalyst is a watch-item rather than an entry.
As read in the same 06 October 2026 session, Clarity Pharmaceuticals retraced from around $9.00 to roughly $1.50 before recovering to about $6.00, with its price action tightening noticeably over the preceding six to eight weeks.
Move | Approximate price |
Prior high | $9.00 |
Retracement low | $1.50 |
Current level | ~$6.00 |
Recent price action | Tightening, last 6-8 weeks |
What Should a Trader Check Before Acting on a Biotech FDA-Approval Setup?
Before treating a biotech's tightening chart as tradeable, two separate checks need to be true at once — a fundamental one and a technical one. The fundamental check is whether the company has actually converted its first approval into commercial revenue, or whether it is still funding itself by returning to the market. The technical check is whether the price action is genuinely tightening into a defined level, or still moving in a wide, undefined range. Gary Glover's anecdotal observation, developed across his trading career, is that both need to align before he sizes a position — and even then, he goes in "pretty light" while a setup is still forming.
Check | Mesoblast (MSB) | Clarity Pharmaceuticals (CU6) |
Fundamental — first approval converted to revenue | Yes | Not yet |
Technical — price tightening into a level | Yes | Yes |
That combination — technical tightening without the fundamental trigger yet confirmed — is why Clarity Pharmaceuticals sits in the watch column rather than the position column for now.
Gary Glover's anecdotal observation, developed across his trading career, is also a note of caution against leaning on a biotech's theoretical market size as a reason to size up before a product has actually proven itself — discussed in relation to Mesoblast's multiple approval pathways during an earlier, 8 September 2026 session:
"I hate using the addressable market term because it's used pretty freely by a lot of stock promoters."
In Gary's framing, a large theoretical market is not a substitute for an approved, revenue-generating product — which is exactly the distinction the two checks above are built to enforce.
For a broader framework on sizing an entry into a tightening setup like these, see how to size a VCP position.
Conclusion
Mesoblast and Clarity Pharmaceuticals currently sit on opposite sides of the same ASX biotech FDA-approval inflection this article set out to explain. FDA approval is what moves a biotech from relying on the market for capital toward potentially earning from its own product, and that shift is as important as anything on the chart. Mesoblast has crossed that line and its price action is tightening to match; Clarity Pharmaceuticals shows the same kind of tightening without yet having crossed it. Gary Glover will be watching for Mesoblast's price to clear its recent lower highs on rising volume, and for Clarity Pharmaceuticals to produce a genuine data or regulatory catalyst — neither is a prediction of what happens next, both are simply what the setup requires before it becomes tradeable. The supporting session recording from 06 October 2026 is accessible to FMP YouTube Momentum Profile members.
The analysis in this article draws on Gary Glover's recorded session on 06 October 2026. Members of the FMP YouTube Momentum Profile receive early access to the educational data that forms the basis of articles like this one. For information on FMP YouTube Momentum Profile membership, visit the FMP membership page.
Remember that past performance is no guarantee of future results, and all trading involves risk.
Frequently Asked Questions
What does FDA approval actually change for an ASX biotech stock?
It moves a biotech from funding itself through the market — issuing new shares to raise capital — toward the possibility of earning revenue directly from sales of the approved product. If the company has further products in related late-stage development, a first approval can also make future approvals more likely without needing fresh capital raises. This shift is fundamental, not technical — it changes the company's economics before it changes its chart.
Why does Gary Glover say Mesoblast's share price needed to "tighten up" before he'd consider it?
Gary Glover's anecdotal observation, developed across his trading career, is that a stock swinging widely between highs and lows is harder to size a position in with a defined risk level. He has watched Mesoblast for months specifically waiting for the wide swings to narrow into a tighter range around its recent low, because a tighter range gives a clearer point to measure risk against.
What is Clarity Pharmaceuticals (CU6) waiting for before its chart setup matters?
Gary Glover's anecdotal observation, developed across his trading career, is that Clarity Pharmaceuticals shows tightening price action similar to Mesoblast's, but without a near-term approval or data catalyst, that technical pattern is a watch-item rather than a trade. A trader applying Gary's framework would look for both the technical tightening and a fundamental trigger before treating it as a setup.
How does a trader size a position in a volatile, pre-catalyst biotech stock?
Gary Glover's anecdotal observation, developed across his trading career, is that sizing small — "going in pretty light" — is appropriate while a setup is still forming and the fundamental catalyst has not yet confirmed. This reflects Gary's general approach to early-stage positioning and is not a recommendation to trade any specific security. For a broader framework on sizing entries, see how to size a VCP position.
What does FMP track to follow ASX momentum stocks like these week to week?
The FMP Momentum Profile — published daily and accessible to FMP YouTube Momentum Profile members — covers the broader ASX momentum universe Gary Glover reviews in his weekly session, giving members early access to the educational data discussed in articles like this one.
About the Author
Christopher Hall, AdvDipFP, is an Authorised Representative (AFSL 526688) and the editorial lead at Finer Market Points, covering ASX-listed momentum stocks and market data for an Australian trading audience. Read more on the author's profile page.
Sources
# | Source | Type |
1 | Gary Glover, Finer Market Points recorded session, 06 October 2026. | Gary Glover session |
2 | Gary Glover, Finer Market Points recorded session, 08 September 2026 (referenced for the "addressable market" observation). | Gary Glover session |
3 | U.S. Food and Drug Administration — approval process (plain description). | External research |
All Gary Glover observations in this article are anecdotal practitioner observations developed across his trading career — not formal studies.
Related Finer Market Points Educational Resources
This article includes a general trading observation made by Gary Glover (AR 259215), Authorised Representative of Novus Capital Limited (AFSL 238 168), during a recorded Finer Market Points session on 06 October 2026. The observation reflects Gary Glover's general approach and his anecdotal observations developed across his trading career — it is general commentary only, and is not a formal study, not financial advice, and not a recommendation to trade any security. It was made in the course of that session and not in response to any individual's circumstances. Content has been edited and summarised by Finer Market Points for educational purposes.
This content is for educational purposes only and does not constitute financial advice. Past performance is no guarantee of future results.
The information, opinions and other materials appearing on this website are of a general nature only and shall not be construed as advice. Finer Market Points Pty Ltd, CAR 1304002, AFSL 526688, ABN 87 645 284 680. This general information is educational only and not financial advice, recommendation, forecast or solicitation. This is not taxation advice. Rose Bay Equities accepts no responsibility for the accuracy or completeness of the information, opinions or other materials provided on or accessible through this website. This website has not been prepared with reference to your individual financial or personal circumstances. You should not rely on any advice on this website without first seeking appropriate professional, financial and legal advice. Further, where Rose Bay Equities makes third party material available or accessible through this website you acknowledge that Rose Bay Equities is a distributor and not a publisher of that content and that its editorial control is limited to the selection of those materials to make available. We accept no liability for any loss or damages arising from use. Authors and presenters may hold positions in discussed companies and investment products.
Comments